Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) (NCT06602193)
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
🩺 Plain-English Summary (8th-Grade Level)
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Department of Neurology — Los Angeles, California
Age range: 30 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Cedars-Sinai Department of Neurology — Los Angeles, California
- University of California San Francisco — San Francisco, California
- Parkinson's Disease and Movement Disorders Center — Boca Raton, Florida
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center — New York, New York
- Evergreen Health Laboratory — Kirkland, Washington
- Inland Northwest Research — Spokane, Washington
- Technische Universität Dresden — Dresden,
- University of Lübeck — Lübeck,
- University Hospital Tübingen — Tübingen,
- Rabin Medical Center — Petah Tikva,
- Movement Disorders Institute, Sheba Medical Center — Ramat Gan,
- Tel Aviv Medical Center — Tel Aviv,
- Hospital Clinic de Barcelona — Barcelona,
- Hospital Universitari General de Catalunya — Barcelona,
- Hospital Universitari Vall d'Hebron — Barcelona,
- Hospital Universitario Donostia — Donostia / San Sebastian,
- Universitary Hospital La Princesa — Madrid,
- IDIVAL/University Hospital Marques de Valdecilla — Santander,
- Hospital Universitario Virgen del Rocio — Seville,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson Disease
- Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation — Tucson, Arizona
- Parkinson's Disease Progression Study — Aurora, Colorado
- To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Birmingham, Alabama
- Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) — Seattle, Washington
- Automated Imaging Differentiation of Parkinsonism — Birmingham, Alabama
- Study in Parkinson Disease of Exercise — Birmingham, Alabama
Explore by condition: All Parkinson Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.